## **Denka**

May 20, 2025 Denka Company Limited

New Building for the Manufacture of Diagnostic Reagents, Including Antigen Detection Kits, Is Now in Operation

Contributing to Global Infectious Disease Prevention and Control Through Expanded
 Production Capacity and Digital Transformation –



< New manufacturing building, Gosen Site Kagamida Plant>

Denka Company Limited (Head Office: Chuo-ku, Tokyo; Representative Director, President: Ikuo Ishida) has completed construction of a new building for the manufacture of rapid antigen diagnostic kits and test reagents at its Gosen Site Kagamida Plant (Gosen-shi, Niigata).

As one of the major domestic manufacturers of test reagents, Denka Company Limited decided to expand its production capacity in April 2022 to meet the growing demand for tests since the COVID-19 pandemic. In the new building, we are working to enhance production efficiency by digitizing operations, production, and logistics processes, such as expanding production capacity for rapid antigen diagnostic kits and test reagents, as well as introducing automated warehouses, automated guided vehicles, and MES (\*1).

Under the "Mission 2030" management plan, Denka Company Limited has been committed to focusing on the Healthcare field. As a manufacturer of test reagents, including rapid antigen diagnostic kits for novel coronavirus, which is at the core of our business, we consider global Infectious disease prevention and control to be our social responsibility, and we will contribute to the expansion of test systems and the improvement of QOL for people around the world.

Denka Company Limited will continue contributing to people's daily lives and society by applying its worldclass chemistry know-how based on the Purpose of Mission 2030: "Make the world a better place as specialists in chemistry."

End of Press Release

(\*1)MES (Manufacturing Execution System)

Information system responsible for visualization/control of each manufacturing process and instruction/support to operators

## [Outline of equipment]

- · Construction site: Gosen Site Kagamida Plant (Gosen-shi, Niigata)
- · Construction scale: Total floor area: 17,000 m<sup>2</sup>, 4 stories above ground
- · Investment amount: Approximately 12.2 billion yen (including related facilities)
- Production capacity: Approximately 2.5 times more rapid antigen diagnostic kits and approximately 2 times more test reagents than current manufacturing facilities
- Product manufactured: POCT (Point Of Care Testing) diagnostic reagents (novel coronavirus, influenza virus, RS virus, etc.)Immunochemistry diagnostic reagents, clinical chemistry diagnostic reagents, bacteriological diagnostic reagents, virological diagnostic reagents, etc.

## [For your reference]

- 1. Outline of Gosen Site (Kagamida Plant, Nigata Plant)
- · Kagamida Plant: 1359-1, Kagamida, Kigoshi, Gosen-shi, Niigata
- · Nigata Plant: 1-2-2, Minami-hon-cho, Gosen-shi, Niigata
- · Number of employees: Approximately 980 (as of April 1, 2025)

[For Inquiries from Media]
Corporate Communications Dept. Tel: +81-3-5290-5511